Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VACC
- Price
- -
- Stock movement down
- -0.09 (-2.90%)
- Company name
- Vaccitech PLC ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 112.26M
- Ent value
- -56.51M
- Price/Sales
- 2.94
- Price/Book
- 0.46
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 9.83
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 27.00%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
VACC does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 9.83 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 7.68 |
| EV to EBITDA | -3.87 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.94 |
| Price to Book | 0.46 |
| EV to Sales | -1.48 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 37.30M |
| EPS (TTM) | 0.30 |
| FCF per share (TTM) | -0.50 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 38.24M |
| Gross profit (TTM) | 38.25M |
| Operating income (TTM) | 5.33M |
| Net income (TTM) | 11.42M |
| EPS (TTM) | 0.30 |
| EPS (1y forward) | -2.31 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.01% |
| Operating margin (TTM) | 13.93% |
| Profit margin (TTM) | 29.85% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 200.10M |
| Net receivables | 10.48M |
| Total current assets | 218.62M |
| Goodwill | 12.63M |
| Intangible assets | 29.06M |
| Property, plant and equipment | 0.00 |
| Total assets | 275.48M |
| Accounts payable | 2.41M |
| Short/Current long term debt | 8.26M |
| Total current liabilities | 14.03M |
| Total liabilities | 31.33M |
| Shareholder's equity | 244.15M |
| Net tangible assets | 202.15M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -12.13M |
| Capital expenditures (TTM) | 6.82M |
| Free cash flow (TTM) | -18.94M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 4.68% |
| Return on Assets | 4.14% |
| Return on Invested Capital | 4.67% |
| Cash Return on Invested Capital | -7.75% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| VACC | S&P500 | |
| Current price drop from All-time high | -82.29% | -1.19% |
| Highest price drop | -90.12% | -56.47% |
| Date of highest drop | 22 Sep 2023 | 9 Mar 2009 |
| Avg drop from high | -61.82% | -10.99% |
| Avg time to new high | 132 days | 12 days |
| Max time to new high | 651 days | 1805 days |
COMPANY DETAILS
Marketcap
112.26M
Marketcap category
Small-cap
Description
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Employees
72
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner